Breast Mesh Lawsuit Attorney

An internal bra sounds reassuring. Patients are often told that surgical mesh can provide internal support, reinforce weakened tissue, improve breast shape, or help hold implants in position. But for many women, the reality has been very different. Instead of a more secure cosmetic or reconstructive result, they have faced chronic pain, inflammation, infection, rippling, firmness, visible contour problems, implant malposition, wound complications, and revision surgery.

At Jeffrey Glassman Injury Lawyers, our breast mesh attorneys are investigating injury claims involving internal bras, when patients were not adequately warned about the true risks. These cases matter because they sit at the intersection of medical-device law, informed consent, product liability, and women’s health. When a device is placed in the body and later fails, rolls, becomes palpable, contributes to complications, or must be removed, the damage is not just physical. It can affect confidence, work, family life, intimacy, and long-term health.

What makes these cases especially serious is that the FDA has stated that no surgical mesh products are cleared or approved for use in breast surgery, including augmentation or reconstruction, and that the agency has not determined their safety and effectiveness. In late 2023, the FDA also issued a letter to health care providers regarding updated BD labeling and reiterated that point directly.

In breast surgery, mesh may be used as a scaffold or support material during augmentation, reconstruction, mastopexy, or revision surgery. Some surgeons and marketers have referred to this use as creating an internal bra, meaning a mesh-based structure intended to support breast tissue or implants from the inside.

One of the products most frequently discussed in current litigation is GalaFLEX. Its FDA 510(k) clearance generally describes it as a transitory scaffold for soft-tissue support and for repairing, elevating, and reinforcing deficiencies in plastic and reconstructive surgery and general soft-tissue reconstruction. But that general clearance is not the same as FDA clearance or approval specifically for breast surgery use. The FDA’s later position is explicit: no mesh products are cleared or approved for use in breast surgery. That distinction is central to many breast-mesh cases.

Breast mesh lawsuits generally focus on several core allegations.

First, patients may claim that device makers failed to provide adequate warnings about the risk of serious complications when mesh was used in breast procedures.

Second, claims may allege that companies promoted or allowed widespread breast use without the level of breast-specific safety and effectiveness evidence that patients reasonably expect for an implanted medical product.

Third, many cases will turn on whether the product performed as represented. If a mesh intended to support tissue instead contributes to rolling, bunching, pain, recurrent ptosis, capsular contracture, infection, drainage, extrusion, or removal surgery, those facts can support a substantial product liability claim depending on the records and expert review.

The FDA’s own adverse-event database contains serious injury reports involving GalaFLEX products used in breast settings, including reports of erythema, seroma, skin inflammation/irritation, ptosis, postoperative wound infection, necrosis, breast pain, capsular contracture, and cases in which removal or revision was reported. An adverse-event report is not the same thing as a legal finding of defect, but it does matter. It helps show that real-world complications have been reported and that the issue is not hypothetical.

Every case is different, but the most serious claims often involve complications such as:

Chronic breast pain or tightness

Infection, drainage, or wound breakdown

Seroma or persistent swelling

Visible or palpable mesh

Mesh rolling, bunching, folding, or failure to support tissue

Implant malposition, bottoming out, or asymmetry

Capsular contracture

Skin irritation, erythema, or necrosis

Extrusion of the implant or mesh

Revision surgery, explant surgery, or repeated reconstruction failure

The practical legal issue is not whether every complication automatically gives rise to a lawsuit. It does not. The real question is whether the patient suffered a significant injury that can be tied to the product, its warnings, its marketing, its design, or the decision-making around implantation. Cases become stronger when the records show a need for corrective surgery, documented post-operative complications, worsening symptoms, or long-term harm.

A strong breast-mesh page has to say this plainly: the FDA has not determined that surgical mesh in breast surgery is safe and effective, and the agency has told health care providers that no mesh products are cleared or approved for use in breast surgery. That is not a minor regulatory footnote. It is one of the most important facts in this litigation.

For injured patients, that matters because many understandably assumed that the FDA had specifically vetted an implanted mesh used in a breast procedure for that purpose. When that assumption turns out to be wrong, the informed-consent and failure-to-warn issues become much more serious.

As of April 6, 2026, breast mesh litigation appears to be in its early stages. The federal JPML pending MDL docket list dated April 1, 2026, includes numerous major product-liability proceedings, such as the Allergan Biocell Textured Breast Implant Products Liability Litigation. Still, it does not show a separate pending MDL specifically for breast mesh or internal-bra claims. That suggests these claims are still emerging and may currently be proceeding through individual filings or early coordinated efforts rather than an established federal MDL.

That distinction is important. A case does not need to wait for a formal MDL to be valid. Many major mass torts begin with scattered individual lawsuits, investigations by plaintiffs’ firms, expert reviews, and growing attention before centralization ever occurs. In other words, the absence of a dedicated breast-mesh MDL right now does not mean the claims are weak. It means the litigation appears to be still maturing.

You may have a potential claim if you had breast mesh implanted during:

Breast augmentation

Breast reconstruction

Breast lift or mastopexy

Revision breast surgery

Correction of implant malposition or recurrent ptosis

Your claim may be stronger if you later experienced:

Pain, infection, swelling, drainage, or redness

A diagnosis of capsular contracture

Visible or palpable mesh

Implant displacement, bottoming out, or reconstruction failure

A recommendation for revision or removal surgery

Explant surgery or additional corrective procedures

The best cases are built with records, not assumptions. That usually means operative reports, implant logs, pathology, follow-up notes, imaging, photographs, and billing records. One of the first things our team looks for is the exact product identification and the surgeon’s description of why the mesh was used and what happened afterward.

A breast mesh claim may seek compensation for:

Past and future medical expenses

Revision surgery and explant costs

Lost income or reduced earning capacity

Physical pain and suffering

Scarring, disfigurement, and loss of body integrity

Emotional distress and psychological harm

Loss of enjoyment of life

In the most serious cases, future reconstructive needs

These are deeply personal injuries. A failed breast-device case is not just another medical bill dispute. It can affect how a person feels in her own body every day.

At Jeffrey Glassman Injury Lawyers, our breast mesh injury attorneys approach dangerous medical-device cases as they should be, with careful factual development, attention to medicine, and a willingness to hold manufacturers accountable when patient safety takes a back seat.

A strong breast mesh case requires more than generic marketing language. It requires a close review of operative records, product identification, complication timelines, and the device's regulatory history. It also requires respect for what clients have actually lived through. These are not abstract claims. They are cases involving women who sought improvement, healing, or reconstruction and instead found themselves facing pain, uncertainty, and additional surgery.

We take that seriously.

If you suspect an internal bra or breast mesh caused complications, do not throw away your paperwork. Request your operative report, implant records, product stickers, pathology records, and all follow-up records. Take photographs if there are visible changes. Keep a timeline of symptoms, medications, infections, drainage, and all procedures following the original surgery.

Most importantly, do not assume you have no case simply because the terminology is confusing. Many patients were never told the exact product name, whether the material was synthetic or biologic, or whether the FDA specifically cleared the use for breast surgery.

That is exactly why legal review matters.

If you suffered complications after an internal bra or breast mesh procedure, contact Jeffrey Glassman Injury Lawyers. We can evaluate the records, identify the product if possible, and determine whether you may have a viable claim involving breast mesh, inadequate warnings, or a developing mass tort.

You trusted that the device placed in your body had been properly tested and properly explained. If that trust was broken, you deserve answers.

Jeffrey Glassman Injury Lawyers
(617) 777-7777